Home » Authors » Jim Shrine

Articles by Jim Shrine

Celldex Starts Phase II/III Trial Of Peptide Vaccine In Brain Cancer

May 25, 2007

NewCo News: Arete Completes $51M Round For New Hypertension Class

May 24, 2007

Genomic Health raises $46.5M to push personalized medicine

May 24, 2007

Phase Forward offering at $90M; Genomic Health raises $45 million

May 24, 2007

NewCo News: Arete Completes $51M Round For New Hypertension Class

May 24, 2007

Genomic Health Raises $46.5M For Personalized Diagnostics

May 23, 2007

Genomic Health Raises $46.5M For Personalized Diagnostics

May 23, 2007

Eurand Raises $112M In IPO For Internal, Collaborative Programs

May 18, 2007

Eurand Raises $112M In IPO For Internal, Collaborative Programs

May 18, 2007

Marcadia Raises $15M In First Round For Metabolic Programs

May 16, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 10, 2025.
FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave
BioWorld MedTech
Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular...
Biopharma exempt from US reciprocal tariffs, but not untouched
BioWorld
At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
Remegen’s lupus drug surfaces with phase III myasthenia gravis data
BioWorld
Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug,...